patient suffering from severe symptomatic primary pulmonary hypertension (PPH) underwent long-term intravenous prostacyclin therapy; the first time for such treatment in Japan. A 26-year-old male had experienced gradually progressive dyspnea for about one year. Despite conventional therapy he suffered repeated syncopal attacks. However, after receiving a permanent central venous access device and a portable infusion pump, he recovered fully and was discharged. This remedy seems to be promising for PPHas has already been proven in Europe and North Americas, although in Japan it is not as yet commercially available and some problems still need to be resolved. (Internal Medicine 36: 794-798, 1997) 
Introduction
Primary pulmonary hypertension (PPH) is a disease of unclear etiology and is characterized by an extreme elevation in pulmonary arterial pressure and pulmonary vascular resistance, ultimately resulting in right ventricular failure and death ( 1-3).
The median survival of patients recorded in the National Institute of Health (NIH) Registry on PPH was 2.8 years after diagnosis (2) . The effects of conventional vasodilating therapy on patients with PPHhave either been inconclusive or mostly disappointing, thus a single lung or heart-lung transplantation (3) has been considered as the only way to improve patient survival. Recently, the clinical efficacy of PGI2 (epoprostenol) has been proven in some trials in Europe (4, 5) and the United States (6) (7) (8) . They have shown that long-term intravenous administration produces marked improvements in both the quality (4-7) and duration of life (8) (Table  1 ). An oximetric study also confirmed no intracardiac shunt. Coronary arteriography was found to be normal, but pulmonary angiography was not performed because of the considerable risk to the patient indicated by the hemodynamicdata, and the absence of major thromboembolic disease as revealed by the perfusion scan described above. These results allowed us to makea final diagnosis of the PPH according to the criteria of the NIH registry on PPH(1).
In spite of limiting the patient to only mild daily activity and only then within his ownroomwith the protection of an oxygen concomitant with isoproterenol at 0.02 jug/kg/min, he recovered completely. After cathecolamines were gradually tapered off, we increased the infusion rate of PGI2 again at increments of 2 ng/kg/min a week up to 8 ng/kg/min, while carefully monitoring changes in systemic arterial pressure and maintaining his general condition.
The patient' s subjective symptoms significantly improved 2 weeksafterthe regimen, and he was able to walk at his ownpace in the hospital without feeling dyspnea. His condition improved from grade IV to III in terms of his NewYork Heart Association (NYHA) functional class. Hemodynamicmeasurements obtained 3 months after the regimen showed a 34%decrease in pulmonary vascular resistance (PVR) and an 18% decrease in the ratio between pulmonaryand systemic vascular resistance (Rp/Rs) ( Table 1) . However, while we were planning to taper off PGI2, he fainted again at rest and gradually deteriorated afterwards. Once again he completely recovered following a gradual increment of PGI2 dosage up to 10 ng/kg/min. Upon evaluation, we realized that the patient was still in serious condition and he wouldnot survive longer without continuous PGI2 infusion.
After obtaining special approval from the Health and Welfare Ministry and the ethical committee of our hospital, and again with the patient's informed consent, in August 1995, we implanted a venous access device for stable and ambulatory PGI2 infusion (Hemed CVAC, Gish Biomedical, Inc., Irvine, California, USA) by inserting a permanent intravenous catheter into the right subclavian vein and then tunneling subcutaneously (Fig. 3) . PGI2 was infused continuously by a portable pump (Ambulatory infusion pump CADD-plus, Smith Industries Medical Systems, USA, Fig. 4 ). Before discharge, the patient was thoroughly trained in the proper techniques of catheter care, asepsis, drug preparation and administration. Finally, in February 1996, he was discharged from our hospital and returned to his hometown in Fukuoka prefecture.
Discussion
Since the description of the characteristic clinical abnormalities over 40 years ago (9), PPHhas been regarded as a progressive, fatal disease that is usually refractory to treatment (1-3). The median survival period of patients with mild to moderate severity is 6 years compared with 2.5 years for class III patients, and only 6 months for class IV patients who were prospectively entered into the NIHRegistry on PPH (2). The present patient was seriously ill before PGI2 therapy in terms of functional class and hemodynamicstatus, and the probability of his survival for one year was estimated as less than 50%based on the NIH Registry data (2). PPHis also pathologically characterized by an extensive remodeling of the pulmonary vasculature, with proliferative changes such as intimal fibrosis, medial hypertrophy, and plexiform lesion (10) . Some coagulopathy (1 1) and functional vasoconstriction (12) also contribute to the progress of this disease. PGI2, as originally discovered by Moncada et al in 1976 (13), is a potent short-acting vasodilator and inhibitor of the platelet aggregation produced by the vascular endothelium.
Its pharmacodynamicproperties are able to influence all of the above pathologic features and inhibit the progression of the disease (14) . Rubin et al were the first to report that at the end of an 8-week randomized study of PPH, patients treated with PGI2 had gained an increase in exercise capacity and improved hemodynamicscompared with those who only received conventional therapy (6) . Ever since, continuous intravenous infusion of PGI2 has been utilized in PPHas a bridge to transplantation for patients enrolled in such programs, and its efficacy is manifested by successful stabilization of patient conditions. The short-term beneficial response to PGI2, characterized by a reduction in pulmonary arterial pressure and increase in cardiac output, also helped to identify those patients with a better prognosis (15) bolic events and temporary interruption to the infusion due to pump malfunction, all of which are potentially life-threatening (17, 18) . But as for alternatives, the effects of long-term oral vasodilating therapy on PPHpatients have so far been inconclusive, except for high-dose calcium channel blockers (19) and beraprost sodium (20), an orally active PGI2 derivative developed in Japan for patients with relatively mild symptoms. In addition, transplantation is not yet approved in Japan. Therefore under such circumstances, at present the continuous intravenous PGI2 therapy seems to be the most promising therapy for severe symptomatic PPHpatients in Japan as well as for those in Europeanand North Americancountries, although the major problems as described above remain to be resolved. To date, unfortunately, intravenous PGI2 is still not commercially available in Japan, even though its short-term beneficial effects and safety have been shown in a multicenter clinical trial (21) and in our ownexperience (22). Swift approval for its appropriate application in patients with severe PPHis an urgent need.
